ArticleMolecular therapy. Oncology2025
GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts.
Reona Okada et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it